The Beninese Agency for Medicines and Other Health Products (Abmaps) ordered the withdrawal of several batches of Croiscard-E from the market in Benin. Officials issued the directive following the identification of a packaging defect affecting the product. This decision mandates that all affected supplies of the medication be removed from circulation to ensure public safety. The regulatory body confirmed that the order specifically targets the identified batches distributed within the country. Abmaps maintains oversight of pharmaceutical standards to prevent the distribution of compromised health products. The agency continues to monitor the situation to confirm that all retailers comply with the withdrawal requirements.
Product Details and Composition
Croiscard-E functions as a 150 ml oral solution formulated to strengthen bones. Mslab manufactures the medication, which incorporates calcium and vitamin D3 as its active components. The 150 ml oral solution is widely utilized by patients seeking to strengthen bones through the administration of its core ingredients, calcium and vitamin D3. By maintaining strict quality control protocols, Abmaps seeks to ensure that every pharmaceutical product distributed under the Mslab label adheres to the necessary safety benchmarks established for the Beninese market.
Officials identified an anomaly in the plastic caps of the containers. This defect could compromise the preservation of the oral solution inside the bottles. The withdrawal is due to an anomaly in the plastic caps that could compromise the product's preservation. Because the structural integrity of the container is essential for maintaining the stability of the liquid formula, the agency determined that the potential for contamination necessitated an immediate recall. The specific nature of the defect involves the plastic caps failing to provide the expected seal, which presents a risk to the long-term viability of the calcium and vitamin D3 solution stored within.
Pharmacies, clinics, and hospitals located in Benin received instructions to remove the affected bottles from their inventories. These health facilities must return the identified stock to their respective wholesalers to finalize the withdrawal process. Pharmacies, clinics, and hospitals in Benin are instructed to remove the affected bottles and return them to wholesalers. This systematic removal process is designed to ensure that no compromised units remain accessible to the public.
The directive issued by Abmaps encompasses the entirety of the supply chain, requiring that all healthcare providers—including pharmacies, clinics, and hospitals—thoroughly audit their current inventory to isolate the batches in question. Once the stock has been identified and removed from the shelves, these facilities are required to coordinate the return of the bottles to their original wholesalers. This procedure aims to centralize the recalled items for proper disposal or further inspection by Mslab. Abmaps remains committed to this enforcement action, regularly communicating with wholesalers to verify that the returned medication is accounted for and removed from the distribution network across Benin.
